Expression profile of cancer-testis genes in transitional cell carcinoma of the bladder

Urologic Oncology: Seminars and Original Investigations

Volumn 30, Issue 6, 2012, Pages 886-892

  Yin, Bo ^a   Liu, Gang ^a   Wang, Xiao Song ^b,c,d   Zhang, Hui ^a   Song, Yong Sheng ^a   Wu, Bin ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^c CCMB   (United States)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MELANOMA ANTIGEN 1; MELANOMA ANTIGEN 3; MESSENGER RNA;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; BLADDER MUCOSA; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CTAGE 1 GENE; CTAGE 2 GENE; CYTOPLASM; FEMALE; GENE EXPRESSION PROFILING; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MAGE A12 GENE; MAJOR CLINICAL STUDY; MALE; NY ESO 1 GENE; PATHOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSITIONAL CELL CARCINOMA; TUMOR GENE;

ADULT; AGED; AGED, 80 AND OVER; BLOTTING, WESTERN; CARCINOMA, TRANSITIONAL CELL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSCRIPTOME; URINARY BLADDER NEOPLASMS; YOUNG ADULT;

EID: 84870551280     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2010.08.017     Document Type: Article

References (26)

1. Patton S.E., Hall M.C., Ozen H. Bladder cancer. Curr Opin Oncol 2002, 14:265-272.
2. Amling C.L. Diagnosis and management of superficial bladder cancer. Curr Probl Cancer 2001, 25:219-278.
3. Nseyo U.O., Lamm D.L. Immunotherapy of bladder cancer. Semin Surg Oncol 1997, 13:342-349. Review.
4. Chen Y.T., Hsu M., Lee P., et al. Cancer/testis antigen CT45: Analysis of mRNA and protein expression in human cancer. Int J Cancer 2009, 124:2893-2898.
5. Zendman A.J., Ruiter D.J., Van Muijen G.N. Cancer/testis-associated genes: Identification, expression profile, and putative function. J Cell Physiol 2003, 194:272-288.
6. Scanlan M.J., Gure A.O., Jungbluth A.A., et al. Cancer/testis antigens: An expanding family of targets for cancer immunotherapy. Immunol Rev 2002, 188:22-32. Review.
7. Scanlan M.J., Simpson A.J., Old L.J. The cancer/testis genes: Review, standardization, and commentary. Cancer Immun 2004, 4:1.
8. van der Bruggen P., Traversari C., Chomez P., et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991, 254:1643-1647.
9. Lin J., Lin L., Thomas D.G., et al. Melanoma-associated antigens in esophageal adenocarcinoma: Identification of novel MAGE-A10 splice variants. Clin Cancer Res 2004, 10:5708-5716.
10. Li M., Yuan Y.H., Han Y., et al. Expression profile of cancer-testis genes in 121 human colorectal cancer tissue and adjacent normal tissue. Clin Cancer Res 2005, 11:1809-1814.
11. Gerhardt A., Usener D., Keese M., et al. Tissue expression and seroreactivity of tumor-specific antigens in colorectal cancer. Cancer Lett 2004, 208:197-206.
12. Usener D., Schadendorf D., Koch J., et al. cTAGE: A cutaneous T cell lymphoma associated antigen family with tumor-specific splicing. J Invest Dermatol 2003, 121:198-206.
13. Mooney S.M., Grande J.P., Salisbury J.L., et al. Sumoylation of p68 and p72 RNA helicases affects protein stability and transactivation potential. Biochemistry 2010, 49:1-10.
14. Kurashige T., Noguchi Y., Saika T., et al. Ny-ESO-1 expression and immunogenicity associated with transitional cell carcinoma: Correlation with tumor grade. Cancer Res 2001, 61:4671-4674.
15. Old L.J., Chen Y.T. New paths in human cancer serology. J Exp Med 1998, 187:1163-1167.
16. Sahin U., Türeci O., Chen Y.T., et al. Expression of multiple cancer/testis (CT) antigens in breast cancer and melanoma: Basis for polyvalent CT vaccine strategies. Int J Cancer 1998, 78:387-389.
17. Scanlan M.J., Altorki N.K., Gure A.O., et al. Expression of cancer-testis antigens in lung cancer: Definition of bromodomain testis-specific gene (BRDT) as a new CT gene, CT9. Cancer Lett 2000, 150:155-164.
18. Kocher T., Schultz-Thater E., Gudat F., et al. Identification and intracellular location of MAGE-3 gene product. Cancer Res 1995, 55:2236-2239.
19. Lonchay C., van der Bruggen P., Connerotte T., et al. Correlation between tumor regression and T cell responses in melanoma patients vaccinated with a MAGE antigen. Proc Natl Acad Sci U S A 2004, 101(Suppl 2):14631-14638.
20. Bolli M., Schultz-Thater E., Zajac P., et al. NY-ESO-1/LAGE-1 coexpression with MAGE-A cancer/testis antigens: A tissue microarray study. Int J Cancer 2005, 115:960-966.
21. Marturano J., Longhi R., Casorati G., et al. MAGE-A3(161-175) contains an HLA-DRβ4 restricted natural epitope poorly formed through indirect presentation by dendritic cells. Cancer Immunol Immunother 2008, 57:207-215.
22. Tsuji K., Hamada T., Uenaka A., et al. Induction of immune response against NY-ESO-1 by CHP-NY-ESO-1 vaccination and immune regulation in a melanoma patient. Cancer Immunol Immunother 2008, 57:1429-1437.
23. Aoki M., Ueda S., Nishikawa H., et al. Antibody responses against NY-ESO-1 and HER2 antigens in patients vaccinated with combinations of cholesteryl pullulan (CHP)-NY-ESO-1 and CHP-HER2 with OK-432. Vaccine 2009, 27:6854-6861.
24. Ait-Tahar K., Liggins A.P., Collins G.P., et al. Cytolytic T-cell response to the PASD1 cancer testis antigen in patients with diffuse large B-cell lymphoma. Br J Haematol 2009, 146:396-407.
25. Natsume A., Wakabayashi T., Tsujimura K., et al. The DNA demethylating agent 5-aza-2'-deoxycytidine activates NY-ESO-1 antigenicity in orthotopic human glioma. Int J Cancer 2008, 122:2542-2553.
26. Bar-Haim E., Paz A., Machlenkin A., et al. MAGE-A8 overexpression in transitional cell carcinoma of the bladder: Identification of two tumor-associated antigen peptides. Br J Cancer 2004, 91:398-407.